Needham Reiterates Their Hold Rating on Regulus (RGLS)

By Ryan Adsit

Needham analyst Alan Carr reiterated a Hold rating on Regulus (RGLSResearch Report) yesterday. The company’s shares closed last Monday at $0.58, close to its 52-week low of $0.50.

According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.3% and a 41.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.

Currently, the analyst consensus on Regulus is a Hold with an average price target of $1.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.07 and a one-year low of $0.50. Currently, Regulus has an average volume of 198.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.